TMPRSS2 and COVID-19: However, when two of the protease inhibitors, Camostat and Nafamostat, employed to demonstrate an important role of TMPRSS2 in SARS-CoV-2 infection in cell culture [5], were employed for COVID-19 treatment in humans, moderate or no efficacy was observed [34].